1. Lanotte M, Hermouet S. Cholera toxin as an intracellular cAMP inducer agent in the regulation of haemopoietic cell development and differentiation. Ann Inst Pasteur/Immunol 1986; 137 D: 201-213.                                 

2. Lanotte M, Hermouet S, Gombaud-Saintonge G, Dobo I. On growth regulation of the rat promyelocytic leukemia (BNML): growth inhibition and eradication of clonogenic cells by cholera toxin. Leuk Res 1986; 10: 1319-1326.                                              


3. Hermouet S, Lanotte M. Cholera toxin resistance associated with deficient adenylate cyclase activity in a subclone of the rat promyelocytic leukemia. Leukemia 1989; 3: 289-293.                     


4. Hermouet S, Milligan G, Lanotte M. Reduction of adenylyl cyclase activity by cholera toxin in myeloid cells. Long term down-regulation of Gs-alpha subunits by cholera toxin treatment. FEBS Lett 1990; 267: 221-225.  


5. Lanotte M, Rivière J-B, Hermouet S, Houge G, Vintermyr OK, Gjertsen BT, Döskeland SO. Programmed cell death (apoptosis) is induced rapidly and with positive cooperativity by activation of cyclic adenosine monophosphate-kinase I in a myeloid leukemia cell line. J Cell Physiol 1991; 146: 73-80.                                    

6. Hermouet S, Merendino JJJr, Gutkind SJ, Spiegel AM. Activating and inactivating mutations of the alpha subunit of Gi2 protein have opposite effects on proliferation of NIH 3T3 cells. Proc Natl Acad Sci USA 1991; 88: 10455-10459. 


7. Kalinec G, Nazarali AJ, Hermouet S, Xu N, Gutkind JS. Mutated alpha subunit of the Gq protein induces malignant transformation in NIH 3T3 cells. Mol Cell Biol 1992, 12: 4687-4693.        

8. Hermouet S, de Mazancourt P, Spiegel AM, Gist Farquhar M, Wilson BS. High level expression of transfected alpha-i3 is required for plasma membrane targeting and adenylyl cyclase inhibition in NIH 3T3 fibroblasts. FEBS Lett 1992; 312: 223-228.                                               


9. Hermouet S, de Mazancourt P, Spiegel AM. Mitogenic effects of pertussis toxin-sensitive G protein alpha-i subunits: the mitogenic action of alpha-i2 in NIH 3T3 cells is mimicked by alpha-i1, but not alpha-i3. Cell Signalling 1993; 5: 215-225. 

10. Hermouet S, Murakami T, Spiegel AM. Stable changes in expression or activation of G protein alpha-i or alpha-q subunits affect the expression of both beta-1 and beta-2 subunits. FEBS Lett 1993; 327: 183-188.                                           

11. Spiegel AM, Weinstein LS, Shenker A, Hermouet S, Merendino JJJr. G proteins: from basic to clinical studies. Adv in Second Messenger and Phosphoprotein Res 1993; 28: 37-46.     


12. Mahé B, Ménard A, Accard F, Pineau D, Robillard N, Hermouet S. In vitro expansion of CD34 cells from peripheral blood of myeloma and lymphoma patients. Nouv Rev Fr Hematol 1995; 37: 335-341.                                               

13. Corre I, Hermouet S. Regulation of CSF-1-induced proliferation by heterotrimeric Gi2 proteins. Blood 1995; 86: 1776-83.


14. Mahé B, Milpied N, Hermouet S, Robillard N, Moreau P, Letortorec S, Rapp M-J, Bataille R, Harousseau J-L. G-CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma and lymphoma. Br J Haematol 1996; 92: 263-268.        

15. Hermouet S, Aznavoorian S, Spiegel AM. In vitro and in vivo growth inhibition of murine melanoma K-1735 cells by a dominant negative mutant alpha subunit of the Gi2 protein. Cell Signalling 1996; 8: 159-166.                                                        

16. Mahé B, Pineau D, Robillard N, Accard F, Hermouet S. Ex vivo expansion of hemopoietic progenitors from CD34+ cells selected from leukapheresis products of lymphoma and myeloma patients: feasibility and enhancement by fibronectin. J Hematother 1996; 5: 671-679.                      


17. Gordeladze JO, Hovik KE, Merendino JJJr, Hermouet S, Gutkind S, Accili D. Effect of activating and inactivating mutations of Gs- and Gi2-alpha protein subunits on growth and differentiation of 3T3-L1 preadipocytes. J Cell Biochem 1997; 64: 242-257.                                    

18. Tenailleau S, Corre I, Hermouet S. Specific expression of heterotrimeric GTP-binding proteins G12 and G16 during human myeloid differentiation. Exp Hematol 1997;25: 927-934.               

19. Spence S, Hermouet S, Houslay MD. Alterations in membrane adenylate cyclase activity in NIH 3T3 cells caused by over-expression of mutant species of the three forms of the inhibitory guanine nucleotide binding protein alpha-Gi. Pharmacol Rev Commun 1997; 9: 1-9.                               

20. Lippert E, Baltensperger K, Jacques Y, Hermouet S. Galpha-16 protein expression is up- and down-regulated following T-cell activation: Disruption of this regulation impairs activation-induced cell responses. FEBS Lett 1997; 417: 292-296.                                               

21. Hermouet S, Niaussat A-E, Briec A, Pineau D, Robillard N, Bataille R, Milpied N, Harousseau J-L, Mahé B. Analysis of platelet recovery after autologous transplantation with G-CSF mobilized CD34+ cells purified from leukapheresis products. Hematol Cell Ther 1997; 39: 317-325      


22. Mossuz P, Dobo I, Genevay M-C, Allegraud A, Dautel M, Niaussat A-E, Cousin F, Praloran V, Boccaccio C, Hermouet S. Use of collagen for standardization of peripheral blood stem cell graft quality evaluation: A multicentric comparative analysis of commercialized collagen-based and methylcellullose-based Colony-Forming Unit assay kits. J Hematother 1998; 7: 351-359.         

23. Zussman A, Hermouet S, Sagi-Eisenberg R. Stimulation of Ca2+-dependent exocytosis in cultured mast cells (RBL-2H3) by a GTPase-deficient mutant of G alpha-i3. Eur J Biochem 1998; 258: 144-149.                                      


24. Corre I, Pineau D, Hermouet S. Interleukin-8: an autocrine/paracrine growth factor for human hematopoietic progenitors acting in synergy with Colony Stimulating Factor-1 to promote monocyte-macrophage growth and differentiation. Exp Hematol 1999; 27: 28-36.                                           

25. Dobo I, Bidet J-M, Acquart S, Allegraud A, Amiot L, Boccaccio C, Boiret N, Domenech J, Mossuz P, Sensebe L, Wunder E, Zandecki M, Hermouet S. Reproducible scoring of CFU-GM and BFU-E grown in collagen-based semi-solid medium after a short (3 h) training. J Hematother 1999; 8: 45-51.                                                

26. Corre I, Baumann H, Hermouet S. Regulation by Gi2 proteins of v-fms-induced proliferation and transformation via Src-kinase and STAT3. Oncogene 1999; 18: 6335-6342.                                  

27. Dobo I, Pineau D, Zandecki M, Hunault M, Hermouet S. Endogenous erythroid and megakaryocytic colony formation in serum-free, cytokine-free collagen gels. J Hematother Stem Cell Res 1999; 8: 601-607.                            


28. Hermouet S, Minvielle S. Inheritance of chromosomally integrated viral DNA? Blood 2000; 95: 1108.                                                                     

29. Hermouet S, Corre I, Lippert E. Interleukin-8 and other agonists of Gi2 proteins: autocrine/paracrine growth factors for human hematopoietic progenitors acting in synergy with Colony Stimulating Factors? Leuk Lymphoma 2000; 38: 39-48.          

30. Lippert E, Jacques Y, Hermouet S. Positive regulation of human T-cell activation by Gi2 proteins and Interleukin-8. J Leukoc Biol 2000; 67: 742-748.      

31. Hermouet S, Corre I, Lippert E. Voies de signalisation des protéines G hétérotrimériques et régulation de l'hématopoïèse. Hématologie 2000; 6: 180-189.                                                     


32. Dobo I, Mossuz P, Campos L, Girodon F, Allégraud A, Latger-Cannard V, Boiret N, Pineau D, Wunder E, Zandecki M, Praloran V, Hermouet S. Comparison of four serum-free, cytokine-free media for analysis of endogenous erythroid colony growth in polycythemia vera and essential thrombocythemia. Hematol J 2001; 2: 396-403.                                                                    

33. Dobo I, Robillard N, Pineau D, Geneviève F, Picard N, Rapp MJ, Boasson M, Zandecki M, Hermouet S. Use of pathology-specific peripheral blood CD34 thresholds to predict leuka-pheresis CD34 content with optimal accuracy: a bicentric analysis of 299 leukaphereses. Annals Hematol 2001; 80: 639-646.           


34. Hermouet S, Godard A, Pineau D, Corre I, Raher S, Lippert E, Jacques Y. Abnormal production of interleukin (IL)-11 and IL-8 in polycythemia vera. Cytokine 2002; 20: 178-183.                


35. Hermouet S, Corre I, Gassin M, Bigot-Corbel E, Sutton CA, Casey JW. Hepatitis C virus, human herpesvirus-8 and the development of plasma cell leukemia. New Engl J Med 2003; 348: 178-179.

36. Hermouet S, Sutton CA, Rose TM, Greenblatt RS, Corre I, Garand R, Neves AM, Bataille R, Casey JW. Qualitative and quantitative analysis of human herpesvirus expression in chronic and acute B-cell lymphocytic leukemia and in multiple myeloma. Leukemia 2003; 17: 185-195.                

37. Girodon F, Hermouet S, Dobo I, Mossuz P. Serum erythropoietin values and endogenous erythroid colony growth in erythrocytoses and essential thrombocythaemia. Br J Haematol 2003; 120: 171.

38. Dobo I, Pineau D, Robillard N, Geneviève F, Picard N, Zandecki M, Hermouet S. Standardization of the CFU-GM assay: advantages of plating a fixed number of CD34+ cells in collagen gels. J Hematother Stem Cell Res 2003; 12: 543-551.   


39. Dobo I, Donnard M, Girodon F, Mossuz P, Boiret N, Boukhari R, Allégraud A, Campos L, Bascans E, Pineau D, Turlure Pascal, Praloran V, Hermouet S. Standardization and comparison of endogenous erythroid colony assay performed with bone marrow or blood progenitors for the diagnosis of polycythaemia vera. Hematol J 2004; 5: 161-167.                                              

40. Mossuz P, Girodon F, Donnard M, Latger-Cannard V, Dobo I, Boiret N, Lecron J-C, Binquet C, Barro C, Hermouet S, Praloran V. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis.  Haematologica 2004; 89: 1194-1198.                                   

41. Dobo I, Boiret N, Lippert E, Girodon F, Donnard M, Mossuz P, Campos L, Pineau D, Bascans E, Praloran V, Hermouet S. A standardized endogenous megakaryocytic /erythroid (EMC/ EEC) colony assay for the diagnosis of essential thrombocythemia. Haematologica 2004; 89: 1203-1208. 

42. Duprez R, Lacoste V, Hermouet S, Troussard X, Valensi F, Merle-Béral H, Gessain A. Plasma-cell leukemia and human herpesvirus 8 infection. Leukemia 2004; 18: 1903-1904.                           

43. Hermouet S, Dobo I, Boiret N, Mossuz P, Girodon F, Lippert E, Donnard M, Latger-Cannard V, Campos L, Praloran V. Standardisation du test de formation de colonies endogènes érythroïdes et mégacaryocytaires en collagène pour le diagnostic des thrombo-cytoses. Hématologie 2004; 10: 2-6.


44. Mossuz P, Girodon F, Hermouet S, Dobo I, Donnard M, Latger-Cannard V, Boiret N,  Praloran V, Lecron J-C. Serum erythropoietin determination by chemiluminescent immunometry: an accurate first intention test for the diagnostic of absolute erythrocytosis. Clin Chemistry 2005; 51: 1018-102

45. Corre-Buscail I, Pineau D, Boissinot M, Hermouet S. Erythropoietin-independent erythroid colony formation by bone marrow progenitors exposed to interleukins 11 and 8. Exp Hematol 2005; 33: 1299-1308.                                     


46. Boissinot M, Garand R, Hamidou M, Hermouet S. The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS). Blood 2006; 108: 1781-1782.   

47. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, Boiret-Dupré N, Skoda RC, Hermouet S. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia  and polycythemia vera. Blood 2006; 108: 1865-1867.

48. Boissinot M, Lippert E, Girodon F, Dobo I, Fouassier M, Masliah C, Praloran V, Hermouet S. Latent myeloproliferative disorder revealed by the JAK2-V617F mutation in patients with splanchnic vein thrombosis and normal or low hematocrit and platelet counts. Blood 2006; 108: 3223-3224.


49. Hermouet S, Dobo I, Lippert E, Boursier M-C, Ergand L, Perrault-Hu F, Pineau D. Comparison of whole blood vs. purified blood granulocytes for the detection and quantitation of JAK2V617F. Leukemia 2007; 21:1128-1130.

50. Girodon F, Lippert E, Mossuz P, Dobo I, Boiret-Dupré N, Lesesve J-F, Hermouet S, Praloran V. JAK2V617F detection and dosage of serum erythropoietin : first steps of the diagnostic work-up for patients consulting for elevated haematocrit. Haematologica 2007; 92: 431-432.

51. Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E, Talmant P, Tichelli A, Hermouet S, Skoda RC. Leukemic blasts in transformed JAK2-V617F positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007; 110: 375-379.

52. Mossuz P, Bouamrani A, Brugière S, Arlotto M, Hermouet S, Lippert E,  Laporte F, Girodon F, Dobo I, Praloran V,  Garin J, Cahn J-Y, Berger F. Apolipoprotein A1: a new serum marker correlated to JAK2 V617F proportion at diagnosis in patients with polycythemia vera. Proteomics Clin Appl 2007; 1: 1605-1612.


53. Neves AM, Thompson G, Carvalheira J, Costa Trindade J, Rueff Tavares J, Caetano JM, Casey JW, Hermouet S. Detection and quantitative analysis of human herpesviruses in pilocytic astrocytomas. Brain Res 2008; 1221: 108-114.

54. Girodon F, Schaeffer C, Cleyrat C, Mounier M, Lafont I, Dos Santos F, Vidal A, Maynadié M, Hermouet S. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxurea therapy. Haematologica 2008; 93: 1723-1727.

55. Bigot-Corbel E, Gassin M, Corre I, Le Carrer D, Delaroche O, Hermouet S. Hepatitis C virus (HCV) infection, monoclonal immunoglobulin specific for HCV core protein, and plasma-cell malignancy. Blood 2008;112: 4357-4358.

56. Mossuz P, Arlotto M, Hermouet S, Bouamrani A, Lippert E, Girodon F, Dobo I, Praloran V, Cahn J-Y, Berger F. Proteomic study of the impact of the JAK2-V617F mutation on the phenotype of Essential Thrombocythemia. Exp Hematol 2008, 36:1642-1647.


57. Lippert E, Girodon F, Hammond E, Reading NS, Jelinek J, Badbaran A, Hanlon K, Hermans M, Richard C, Swierczek S, Ugo V, Carillo S, Harrivel V, Marzac C, Pietra D, Sobas M, Migeon M, Ellard S, Fehse B, Hermans R, Prchal JT, Skoda RC, Hermouet S. Concordance of assays designed for the quantitation of JAK2V617F (1849G>T): a multi-centre study. Haematologica 2009; 94: 38-45.

58. Schaub FX, Jäger R, Looser R, Hao-Shen H, Hermouet S, Girodon F, Tichelli A, Gisslinger H, Kralovics R, Skoda RC. Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the pre-disposing mutations for JAK2-V617F. Blood 2009; 113: 2022-2027.

59. Fouassier M, Girodon F, Cleyrat C, Robillard N, Garand R, Hermouet S. Absence of JAK2-V617F in paroxysmal nocturnal hemoglobinuria-associated thrombosis.  Thromb Haemost 2009; 102: 180-182.


60. Cleyrat C, Jelinek J, Girodon F, Boissinot M, Ponge T, Harousseau J-L, Issa J-P, Hermouet S. JAK2 mutation and disease phenotype: A double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5. Leukemia 2010; 24:1069-1073.


61. Boissinot M, Cleyrat C, Vilaine M, Jacques Y, Corre I, Hermouet S. Anti-inflammatory hepatocyte growth factor and interleukin-11 are overexpressed in Polycythemia Vera and contribute to the growth of mutated erythroblasts independently of JAK2V617F. Oncogene 2011;30:990-1001

62. Carillo S, Henry L, Lippert E, Girodon F, Guiraud I, Richard C, Dubois-Galopin F, Cleyrat C, Jourdan E, Kralovics R, Hermouet S, Lavabre-Bertrand T. Nested high resolution melting curve (HRM) analysis: a highly sensitive, reliable and simple method for the detection of JAK2 exon 12 mutations: clinical relevance in the monitoring of polycythemia. J Mol Diagn 2011; 13:263-270.

63. Girodon F, Steinkamp MP, Cleyrat C, Hermouet S, Wllson BW. Confocal imaging studies cast doubt on nuclear localisation of Jak2V617F.  Blood 2011; 118: 2633-2634.

64. Hermouet S, Vilaine M. The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection? Haematologica 2011;96:1575-9.

65. Vilaine M, Olcaydu D, Harutyunyan A, Bergeman J, Mourad T, Ramée J-F, Chen J-M, Kralovics R, Hermouet S. Homologous recombination of wild-type JAK2, a novel early step in he development of myeloproliferative neoplasm. Blood 2011; 118: 6468-6470.


66. Leveau C, Vilaine M, Hermouet S. Inflammation and clone evolution in myelo-proliferative neoplasms: Interest of combining drugs that target inflammation-linked cytokines and their signaling pathways. Blood 2012; e-Letter (in response to Hasselbalch HC. Perspectives on chronic inflam-mation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 2012 ; 119:3219-322

67. Broseus J, Florensa L, Zipperer E, Schnittger S, Malcovati L, Richebourg S, Lippert E, Cermak J, Evans J, Mounier M, Raya JM, Bailly F, Gattermann N, Haferlach T, Garand R, Allou K, Besses C, Germing U, Haferlach C, Travaglino E, Luno E, Pinan MA, Arenillas L, Rozman M, Perez Sirvent ML, Favre B, Guy J, Alonso E, Ahwij N, Jerez A, Hermouet S, Maynadié M, Cazzola M, Girodon F. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica 2012; 97:1036-1041.


68. Féron D, Charlier C, Gourain V, Garderet L, Coste-Burel M, Le Pape P, Weigel P, Jacques Y, Hermouet S, Bigot-Corbel  E. Multiplexed infectious protein microarray immunoassay suitable for the study of the specificity of monoclonal immunoglobulins. Analytical Biochemistry 2013; 433:202-209.

69. Cario H, McMullin MF, Bento C, Pospisilova D, Percy MJ, Hussein K, Schwarz J, Aström M, Hermouet S. Erythrocytosis in children and adolescents -classification, characterization, and consensus recommendations for the diagnostic approach. Pediatr Blood Cancer 2013; 60:1734-38.

70. Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, Pallisgaard N, Maroc N, Hermouet S, et al. Establishing Optimal Quantitative-Polymerase Chain Reaction Assays for Routine Diagnosis and Tracking Minimal Residual Disease in JAK2-V617F Associated Myeloid Neoplasms: A Joint European LeukemiaNet/MPN&MPNr-EuroNet (COST Action BM0902) Study. Leukemia 2013; 27(10):2032-2039.


71. Hussein K, Percy M, McMullin MF, Schwarz J, Schnittger S, Porret N, Martinez-Aviles LM, Giraudier S, Bellosillo Paricio B, Holger Cario H, Skoda R, Lippert E, Hermouet S. Clinical utility gene card for: Hereditary thrombocytosis. Eur J Human Genet 2014 Feb; 22 (2).

72. Bento C, Percy MJ, Gardie B, Maia TM, van Wijk R, Perrotta S, Ragione FD, Almeida H, Rossi C, Girodon F, Aström M, Neuman D, Schnittger S, Landin B, Minkov M, Randi ML, Casadevall N, Vainchenker W, Rives S, Hermouet S, Ribeiro L, McMullin MF, Cario H; on behalf of ECE-Consortium. Genetic basis of Congenital Erythrocytosis: mutation update and online databases. Hum Mutation 2014; Jan;35(1):15-26.

73. Lippert E, Mansier O, Migeon M, Denys B, Nilson A, Rosmond C, Lodé L, Ugo V, Lascaux A, Bellosillo-Paricio B, Martinez-Lopez J, Naguib D, Gachard N, Maroc N, Hermouet S. Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis. Haematologica 2014; 99 (7): e098-101.

74. Almouzni G, Altucci L, Amati B, Ashley N, Baulcombe D, Beaujean N, Bock C, Bongcam-Rudloff E, Bousquet J, Braun S, Bressac de Paillerets B, Bussemakers M, Clarke L, Conesa A, Estivill X, Fazeli A, Grgurevi N, Gut I, Halazonetis T, Heijmans BT, Hermouet S et al.Relationship between genome and epigenome'' Workshop report.  BMC Genomics 2014; 15(1): 487.

75. Cleyrat C, Dareshouri A, Steinkamp MP, Vilaine M, Boassa D, Ellisman MH, Hermouet S, Wilson BS. Mpl traffics to the cell surface through unconventional and conventional routes.  Traffic 2014; 15(9): 961-982.

76. Boissinot M, Vilaine M, S. Hermouet. The hepatocyte growth factor (HGF)/c-MET axis: A neglected target in the treatment of chronic myeloproliferative neoplasms? Review. Cancers (Basel) 2014; 6(3): 1631-1669.

77. Gardie B, Hermouet S. Chapitre du livre Erythrocytoses héréditaires. Traité de Médecine, 5e édition, Médecine Sciences-Publications/Lavoisier. 2014.

78. Broséus J, Park J-H, Serge Carillo S, Hermouet S, Girodon F. Presence of calreticulin mutations in JAK2-negative polycythemia vera. Blood 2014; 124(26):3964-6.


79. Barosi G, Tefferi A, Besses C, Birgegard G, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Harrison C, Hehlmann R, Hermouet S, Kiladjian J-J, Kröger N, Mesa R, McMullin M-F, Pardanani A, Passamonti F, Samuelsson J, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tognoni G, Barbui T. Clinical endpoints for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from ELN and IWG-MRT.  Leukemia 2015;29(1):20-6. Review.

80. Langabeer SE, Andrikovics H, Asp J, Bellosillo B, Carillo S, Haslam K, Kjaer L, Lippert E, Mansier O, Oppliger Leibundgut E, Percy MJ, Porret M, Palmqvist L, Schwarz J, McMullin M-F, Schnittger S, Pallisgaard N, Hermouet S, on behalf of the MPN&MPNr-EuroNet. Molecular diagnostics of myeloproliferative neoplasms (MPN). Eur J Hematol 2015 Oct;95(4):270-9.

81. Hermouet S. Pathogenesis of myeloproliferative neoplasms: More than mutations. Exp Hematol 2015 Oct 8. pii: S0301-472X(15)00661-X. doi: 10.1016/j.exphem.2015.08. 014.

82. Hermouet S, Hasselbalch HC, Cokic V. Mediators of inflammation in myeloproliferative neoplasms: State of the Art. Mediators Inflamm 2015; 964613. doi: 10.1155/2015/964613. Editorial.

83. Hermouet S, Bigot-Corbel E, Gardie B. Pathogenesis of myeloproliferative neoplasms: Role and mechanisms of chronic inflammation. Mediators Inflamm 2015; 145293. doi: 10.1155/2015/145293. Review.